Skip to Main content Skip to Navigation
Journal articles

Redifferentiation-facilitated radioiodine therapy in thyroid cancer

Abstract : Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary data obtained in a small series of patients were encouraging and this strategy might become an alternative treatment in those patients with a druggable mutation that induces a stimulation of the MAP kinase pathway. This is an active field of research to answer many still unresolved questions.
Complete list of metadata
Contributor : Corinne DUPUY Connect in order to contact the contributor
Submitted on : Thursday, November 25, 2021 - 8:18:33 AM
Last modification on : Saturday, June 25, 2022 - 3:45:27 AM
Long-term archiving on: : Saturday, February 26, 2022 - 6:04:25 PM


Files produced by the author(s)



Livia Lamartina, Nadège Anizan, Corinne Dupuy, Sophie Leboulleux, Martin Schlumberger. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocrine-Related Cancer, BioScientifica, 2021, 28 (10), pp.T179-T191. ⟨10.1530/ERC-21-0024⟩. ⟨hal-03445754⟩



Record views


Files downloads